IDH1 and cancer: Most of these IDH1/2 alterations are heterozygous missense mutations that confer a neomorphic activity on the encoded enzymes, such that they convert α-ketoglutarate to (R)-2-hydroxyglutarate (2HG), identified as an oncometabolite that contributes to the malignant phenotype in these cancers [1].